Zymes LLC announced that it has successfully solubilized fish oil and Omega-3 fatty acids (DHA/EPA/ALA). Zymes' solubilization technology, Ubisol-Aqua(TM), provides a superior platform for solubilizing omega-3 fatty acids and other water- insoluble lipophilic compounds for foods, beverages, nutritional supplements, pharmaceuticals and cosmetics. The technology, available for licensing, provides improved solubility, enhanced bioavailability and particle size reduction to the nanometer level. Zymes new water-soluble formulation of omega-3 fatty acids is another major breakthrough for the many industries looking to supplement their products with functional ingredients.
To achieve solubilization, Ubisol-Aqua(TM) uses nanotechnology and complexation to reformulate and improve solubility of drugs, nutrient and cosmetic ingredients that are water-insoluble and therefore difficult for the human body to absorb. Using this combined approach, Zymes delivers new water- soluble omega-3 fatty acids with an average particle size of 34 nanometers.
"Achieving solubility of fish oil and omega-3 fatty acids creates additional opportunities to bring our Ubisol-Aqua(TM) technology to the food, beverage and nutritional markets around the world," said Benjamin D. Mamola, Co-founder and Executive Vice President of Global Business Development at Zymes. "Our new breakthrough technology makes it possible to more effectively deliver omega-3 fatty acids in foods and beverages. We believe the technology will greatly enhance the health benefits of these products to consumers."
Zymes offers its delivery system technology to industry partners in need of more effective ways of making their ingredients water-soluble and thus more bioavailable.
Zymes LLC is a bio-science company that combines science, technology and nature to create products that improve the quality of life. It is dedicated to contributing to the well-being of individuals by developing high-quality products that provide significant, clinically-proven health and beauty benefits to consumers. Based in Hasbrouck Heights, NJ, Zymes holds substantial intellectual property ranging from production of synthetic CoQ10 to pharmaceutical drug delivery systems. For more information, visit the Zymes website at http://www.zymesllc.com or email [email protected].
201-727-1520 ext 110,
201-727-1520 ext 110,